Kwality Pharmaceuticals (KPL) Stock Overview
Together with its subsidiary, manufactures finished pharmaceutical formulations in India and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
KPL Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Kwality Pharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹2,439.30 |
| 52 Week High | ₹2,600.00 |
| 52 Week Low | ₹1,561.00 |
| Beta | 0.34 |
| 1 Month Change | 5.62% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 46.72% |
Recent News & Updates
Recent updates
Shareholder Returns
| KPL | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -1.8% | 2.0% | -0.5% |
| 1Y | n/a | 10.6% | -2.3% |
Return vs Industry: Insufficient data to determine how KPL performed against the Indian Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how KPL performed against the Indian Market.
Price Volatility
| KPL volatility | |
|---|---|
| KPL Average Weekly Movement | 7.6% |
| Pharmaceuticals Industry Average Movement | 7.1% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in IN Market | 9.9% |
| 10% least volatile stocks in IN Market | 4.4% |
Stable Share Price: KPL has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: Insufficient data to determine KPL's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1983 | 997 | Ramesh Arora | www.kwalitypharma.com |
Kwality Pharmaceuticals Limited, together with its subsidiary, manufactures finished pharmaceutical formulations in India and internationally. The company offers its products in various dosage forms, including liquid orals, powder for oral suspension, dry syrups, tablets, capsules, sterile powder for injections, small volume parentals (liquid and lyophilized), pre filled syringes, ointments and creams, ophthalmic preparations, eye/ear drops, sanitizers, suppositories, injectable vials and ampoules, lyophilized products, syrups, daunorubicin, and various other categories such as general, beta-lactam, cephalosporins, cytotoxic (oncology), and biological. It also provides intermediates, chemicals, extracts, alkaloids, toilet requisites, beverages, and other medical preparations.
Kwality Pharmaceuticals Limited Fundamentals Summary
| KPL fundamental statistics | |
|---|---|
| Market cap | ₹25.22b |
| Earnings (TTM) | ₹673.46m |
| Revenue (TTM) | ₹5.03b |
Is KPL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KPL income statement (TTM) | |
|---|---|
| Revenue | ₹5.03b |
| Cost of Revenue | ₹2.58b |
| Gross Profit | ₹2.45b |
| Other Expenses | ₹1.77b |
| Earnings | ₹673.46m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 64.90 |
| Gross Margin | 48.63% |
| Net Profit Margin | 13.39% |
| Debt/Equity Ratio | 39.5% |
How did KPL perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/28 16:24 |
| End of Day Share Price | 2026/06/25 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2026/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Kwality Pharmaceuticals Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.